BR112019006571A2 - derivados de éter de isoxazolila como gaba a alfa5 pam - Google Patents
derivados de éter de isoxazolila como gaba a alfa5 pamInfo
- Publication number
- BR112019006571A2 BR112019006571A2 BR112019006571A BR112019006571A BR112019006571A2 BR 112019006571 A2 BR112019006571 A2 BR 112019006571A2 BR 112019006571 A BR112019006571 A BR 112019006571A BR 112019006571 A BR112019006571 A BR 112019006571A BR 112019006571 A2 BR112019006571 A2 BR 112019006571A2
- Authority
- BR
- Brazil
- Prior art keywords
- alpha5
- gaba
- pam
- ether derivatives
- isoxazolyl
- Prior art date
Links
- LRJJZSXDNXHKQV-UHFFFAOYSA-N 3-(1,2-oxazol-3-yloxy)-1,2-oxazole Chemical class C1=CON=C1OC=1C=CON=1 LRJJZSXDNXHKQV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
a presente invenção refere-se a novos compostos que têm a fórmula geral (i) (i) em que r1, r2, r3, r4, r5, r6, x, y e z são como descritos aqui, composições incluindo os compostos e métodos de uso dos compostos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16202889 | 2016-12-08 | ||
| PCT/EP2017/081768 WO2018104419A1 (en) | 2016-12-08 | 2017-12-07 | New isoxazolyl ether derivatives as gaba a alpha5 pam |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019006571A2 true BR112019006571A2 (pt) | 2019-07-02 |
Family
ID=57530563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019006571A BR112019006571A2 (pt) | 2016-12-08 | 2017-12-07 | derivados de éter de isoxazolila como gaba a alfa5 pam |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11091471B2 (pt) |
| EP (1) | EP3551627B1 (pt) |
| JP (1) | JP7084405B2 (pt) |
| KR (1) | KR102564643B1 (pt) |
| CN (2) | CN117285525A (pt) |
| AR (1) | AR110498A1 (pt) |
| AU (1) | AU2017373734B2 (pt) |
| BR (1) | BR112019006571A2 (pt) |
| CA (1) | CA3040024A1 (pt) |
| CL (1) | CL2019001458A1 (pt) |
| CO (1) | CO2019002692A2 (pt) |
| CR (1) | CR20190268A (pt) |
| DK (1) | DK3551627T3 (pt) |
| ES (1) | ES2910110T3 (pt) |
| HR (1) | HRP20220468T1 (pt) |
| HU (1) | HUE058355T2 (pt) |
| IL (1) | IL267054B (pt) |
| LT (1) | LT3551627T (pt) |
| MA (1) | MA48594B1 (pt) |
| MX (1) | MX2019006696A (pt) |
| PE (1) | PE20191156A1 (pt) |
| PH (1) | PH12019500664A1 (pt) |
| PL (1) | PL3551627T3 (pt) |
| PT (1) | PT3551627T (pt) |
| RS (1) | RS63106B1 (pt) |
| SI (1) | SI3551627T1 (pt) |
| TW (1) | TWI642666B (pt) |
| UA (1) | UA125524C2 (pt) |
| WO (1) | WO2018104419A1 (pt) |
| ZA (1) | ZA201902225B (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110498A1 (es) | 2016-12-08 | 2019-04-03 | Hoffmann La Roche | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 |
| CA3102101A1 (en) | 2018-06-13 | 2019-12-19 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物 |
| US20240043418A1 (en) * | 2020-03-26 | 2024-02-08 | Richter Gedeon Nyrt. | 1,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators |
| CA3216863A1 (en) | 2021-05-05 | 2022-11-10 | University College Cardiff Consultants Limited | Heteroaryl compounds useful in the treatment of cognitive disorders |
| HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| WO2023247389A1 (en) | 2022-06-20 | 2023-12-28 | F. Hoffmann-La Roche Ag | Crystalline forms of 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4- yl)methoxy)-n-(tetrahydrapyran-4-yl)pyridazine-3-carboxamide |
| WO2024088928A1 (en) | 2022-10-25 | 2024-05-02 | F. Hoffmann-La Roche Ag | Process for manufacturing alogabat |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0810019A2 (pt) * | 2007-04-18 | 2014-10-14 | Astrazeneca Ab | Composto, composição farmacêutica, e, uso de um composto |
| EP2767536B1 (en) * | 2007-12-04 | 2015-09-02 | F. Hoffmann-La Roche AG | Isoxazolo-pyridine derivatives |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8222246B2 (en) * | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| AU2010244553A1 (en) | 2009-05-05 | 2011-12-01 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| US8835425B2 (en) * | 2010-11-05 | 2014-09-16 | Hoffmann-La Roche Inc. | Use of selective GABA A α5 negative allosteric modulators for the treatment of central nervous system conditions |
| MY169043A (en) * | 2011-09-15 | 2019-02-07 | Hoffmann La Roche | New dihydroquinoline-2-one derivatives |
| CU20180019A7 (es) | 2015-08-17 | 2018-06-05 | Lupin Ltd | Derivados de heteroarilo como inhibidores de parp |
| KR20180100638A (ko) | 2016-01-08 | 2018-09-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 5'-뉴클레오티다아제, 엑토의 조절제, 및 이의 용도 |
| ES2832475T3 (es) | 2016-01-08 | 2021-06-10 | Celgene Corp | Compuestos antiproliferativos y sus composiciones farmacéuticas y usos |
| AR110498A1 (es) | 2016-12-08 | 2019-04-03 | Hoffmann La Roche | DERIVADOS DE ISOXAZOLIL ÉTER COMO MODULADORES ALOSTÉRICOS POSITIVOS (PAM) DE RECEPTORES DE GABAA a5 |
-
2017
- 2017-12-07 AR ARP170103429A patent/AR110498A1/es unknown
- 2017-12-07 MX MX2019006696A patent/MX2019006696A/es unknown
- 2017-12-07 HU HUE17816630A patent/HUE058355T2/hu unknown
- 2017-12-07 HR HRP20220468TT patent/HRP20220468T1/hr unknown
- 2017-12-07 CN CN202311216893.9A patent/CN117285525A/zh active Pending
- 2017-12-07 BR BR112019006571A patent/BR112019006571A2/pt active Search and Examination
- 2017-12-07 EP EP17816630.2A patent/EP3551627B1/en active Active
- 2017-12-07 RS RS20220321A patent/RS63106B1/sr unknown
- 2017-12-07 JP JP2019530755A patent/JP7084405B2/ja active Active
- 2017-12-07 CA CA3040024A patent/CA3040024A1/en active Pending
- 2017-12-07 UA UAA201907047A patent/UA125524C2/uk unknown
- 2017-12-07 PL PL17816630T patent/PL3551627T3/pl unknown
- 2017-12-07 CN CN201780069758.2A patent/CN109923113B/zh active Active
- 2017-12-07 ES ES17816630T patent/ES2910110T3/es active Active
- 2017-12-07 SI SI201731124T patent/SI3551627T1/sl unknown
- 2017-12-07 PT PT178166302T patent/PT3551627T/pt unknown
- 2017-12-07 KR KR1020197016011A patent/KR102564643B1/ko active IP Right Grant
- 2017-12-07 MA MA48594A patent/MA48594B1/fr unknown
- 2017-12-07 WO PCT/EP2017/081768 patent/WO2018104419A1/en active Application Filing
- 2017-12-07 PE PE2019001006A patent/PE20191156A1/es unknown
- 2017-12-07 CR CR20190268A patent/CR20190268A/es unknown
- 2017-12-07 TW TW106142872A patent/TWI642666B/zh active
- 2017-12-07 AU AU2017373734A patent/AU2017373734B2/en active Active
- 2017-12-07 DK DK17816630.2T patent/DK3551627T3/da active
- 2017-12-07 LT LTEPPCT/EP2017/081768T patent/LT3551627T/lt unknown
-
2019
- 2019-03-26 CO CONC2019/0002692A patent/CO2019002692A2/es unknown
- 2019-03-27 PH PH12019500664A patent/PH12019500664A1/en unknown
- 2019-04-09 ZA ZA2019/02225A patent/ZA201902225B/en unknown
- 2019-05-29 CL CL2019001458A patent/CL2019001458A1/es unknown
- 2019-06-03 IL IL267054A patent/IL267054B/en unknown
- 2019-06-05 US US16/432,584 patent/US11091471B2/en active Active
-
2021
- 2021-07-16 US US17/378,410 patent/US20220411415A1/en not_active Abandoned
-
2024
- 2024-02-28 US US18/590,606 patent/US20240279218A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019006571A2 (pt) | derivados de éter de isoxazolila como gaba a alfa5 pam | |
| BR112015022804A2 (pt) | novos derivados de octahidro-pirrol [3,4-c]-pirrol e seus análogos como inibidores de autotaxina | |
| BR112018006034A2 (pt) | compostos bicíclicos como inibidores de atx | |
| BR112018006080A2 (pt) | novos compostos bicíclicos como inibidores de dupla ação de atx/ca | |
| BR112017006829A2 (pt) | derivados de espirodiamina como inibidores de aldosterona sintase | |
| CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
| BR112014030473A2 (pt) | novo diazaespirocicloalcano e azaespirocicloalcano | |
| BR112018003812A2 (pt) | compostos de heteroarila como inibidores de irak e usos dos mesmos | |
| BR112017027414A2 (pt) | Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo | |
| BR112014010644A2 (pt) | novos derivados de aril-quinolina | |
| BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
| EA201691799A1 (ru) | Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) | |
| BR112017026682A2 (pt) | novos compostos bicíclicos como inibidores de dupla ação de atx/ca | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| TR201900038T4 (tr) | GPR6'nın tetrahidropiridopirazin modülatörleri. | |
| EA201690473A1 (ru) | Комбинированный состав двух противовирусных соединений | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
| BR112017018305A2 (pt) | desacetoxitubulisina h e análogos da mesma | |
| BR112014018943A8 (pt) | Composições pesticidas e processos relacionados as mesmas | |
| BR112016009757A8 (pt) | “inibidores do vírus sincicial respiratório com base em quinazolina” | |
| BR112023003580A2 (pt) | Compostos heterocíclicos | |
| BR112023023527A2 (pt) | Inibidores de nlrp3 | |
| BR112022003982A2 (pt) | Compostos heterocíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |